Welcome to Hmobio!Global leader in active molecules.
Find Your Distributors

Select Your Country or Region

 $ USD

For research purposes only. Not for human experiments
You are here:Home-Research Areas-Infection-RSV Infection

Request The Product List ofRSV Infection RSV Infection

Respiratory syncytial (sin-SISH-uhl) virus, or RSV, is a common respiratory virus that usually causes mild, cold-like symptoms. Most people recover in a week or two, but RSV can be serious, especially for infants and older adults. In fact, RSV is the most common cause of bronchiolitis (inflammation of the small airways in the lung) and pneumonia (infection of the lungs) in children younger than 1 year of age in the United States. It is also a significant cause of respiratory illness in older adults.

Cat. No. Product Name CAS No. Information
H1527

Ziresovir

 		1422500-60-4

Ziresovir (AK-0529, AK0529) is a novel RSV F-protein inhibitor for treatment of Hospitalized Respiratory Syncytial Virus (RSV) fnfection.
H1525

VP-14637

 		235106-62-4

VP-14637 (MDT-637) is a novel RSV fusion inhibitor with EC50 of 1.4 nM, reduces RSV replication by inhibition of the F-protein function; does not block RSV adsorption but inhibits RSV-induced cell-cell fusion and binds specifically to RSV-infected cells, specifically interacts with the RSV fusion protein expressed by a T7 vaccinia virus system; the F proteins containing the resistance mutations exhibits greatly reduced binding of VP-14637.
H1523

RV521

 		1903763-82-5

Sisunatovir is a potent, orally active, small-molecule inhibitor of RSV fusion, demonstrates potent antiviral activity across multiple strains of RSV in vitro.
H1520

RSV604

 		676128-63-5

RSV604 (RSV-604) is a potent respiratory syncytial virus (RSV) inhibitor with EC50 of 0.86 uM in XTT assay, targets the nucleocapsid protein and is active post-RSV infection; RSV604 is also equipotent against 40 clinical isolates of RSV with an average EC50 of 0.8 μM by plaque reduction assay; The mutations (N105D, I129L, L139I, and I129L with L139I) within the nucleocapsid protein confer 5->20-fold reduced potentcy for RSV604; inhibits virus replication after mucosal inoculation in human airway epithelial cell model (EC50=0.5-0.9 uM).
H1518

Presatovir

 		1353625-73-6

Presatovir (GS-5806) is a novel, orally bioavailable RSV fusion inhibitor with mean EC50 of 0.43 nM against a panel of 75 RSV A and B clinical isolates; exhibits low cytotoxicity in human cell lines and primary cell cultures (selectivity > 23,000-fold); shows excellent antiviral efficacy in the cotton rat model of RSV infection.
H1517

PC786

 		1902114-15-1

PC786 (PC-786)is a potent non-nucleoside RSV L-protein polymerase inhibitor with IC50 of 2.1 nM and 0.5 nM in cell-free enzyme assay and mini-genome assay in HEp-2 cells, respectively; demonstrates a potent and selective anti-viral activity against laboratory adapted or clinical isolates of RSVA (IC50=<0.09-0.71 nM) and RSVB (IC50=1.3-50.6 nM) without causing detectable cytotoxicity.
H1516

JNJ-53718678

 		1383450-81-4

Rilematovir (JNJ53718678, JNJ-678) is a potent (Kd=7.4 nM), small-molecule inhibitor of the F-glycoprotein-mediated complex membrane fusion process of the RSV; displays very potent antiviral activity and low cytotoxicity; inhibits ESV replication in HBECs with IC50 of 1.2 nM, efficiently inhibits RSV infection in vivo.
H1515

JNJ-2408068

 		317846-22-3

A potent RSV fusion inhibitor with EC50 of 0.16 nM against some lab strains; diplays almost 100,000 times better than that of ribavirin (EC50=15 uM); also inhibits the release of proinflammatory cytokines IL-6, IL-8 and Rantes from RSV-infected A549 cells.
H1513

Enzaplatovir

 		1323077-89-9

Enzaplatovir (BTA-585, BTA-C585) is an orally bioavailable RSV fusion protein inhibitor for the treatment of respiratory syncytial virus infections.
H1510

AZD-4316

 		1243324-08-4

A potent respiratory syncytial virus (RSV) fusion inhibitor.

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
© Copyright 2020 HmoBio. All Rights Reserved. Products are only for research use
沪ICP备2020027822号-1